戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2.
2 protein particles and is also referred to as lipoprotein-associated phospholipase A2.
3 lesterol, 16.2% for interleukin-6, 18.5% for lipoprotein-associated phospholipase A2, 21.9% for high-
4 idase (156+/-19 versus 89+/-8 ng/mL), higher lipoprotein-associated phospholipase A2 (242+/-12 versus
5  vs 0.30 mmol/L, 0.04 to 0.55, p<0.0001) and lipoprotein-associated phospholipase A2 (-52.2 ng/mL, 95
6 cellular adhesion molecule 1, interleukin-6, lipoprotein-associated phospholipase A2 activity and mas
7                                     Elevated lipoprotein-associated phospholipase A2 activity promote
8 verall, women had higher levels of hsCRP and lipoprotein-associated phospholipase A2 after AMI compar
9                                              Lipoprotein-associated phospholipase A2, also known as p
10   Plasma N-terminal-proANP, myeloperoxidase, lipoprotein-associated phospholipase A2, and oxidized lo
11                           Elevated levels of lipoprotein-associated phospholipase A2 appear to be a s
12 inhibitors of secretory phospholipase A2 and lipoprotein-associated phospholipase A2 are potential ca
13 ed with absent enzymatic activity of soluble lipoprotein-associated phospholipase A2; at CYP2F1, with
14                                              Lipoprotein-associated phospholipase A2, C-reactive prot
15 nogen, factor VII, apolipoproteins AI and B, lipoprotein-associated phospholipase A2, homocysteine or
16 utcome trials secretory phospholipase A2 and lipoprotein-associated phospholipase A2 inhibition.
17          Both secretory phospholipase A2 and lipoprotein-associated phospholipase A2 inhibitors hold
18 rrant additional investigation of this novel lipoprotein-associated phospholipase A2 inhibitory mecha
19                                              Lipoprotein-associated phospholipase A2 levels in the se
20                                              Lipoprotein-associated phospholipase A2 (Lp PLA2) is pos
21     Secretory phospholipase A2 (sPLA(2)) and lipoprotein-associated phospholipase A2 (Lp-PLA(2)) are
22 h-sensitivity C-reactive protein (hsCRP) and lipoprotein-associated phospholipase A2 (Lp-PLA(2)).
23                     Elevated levels of human lipoprotein-associated phospholipase A2 (Lp-PLA2) are as
24                                              Lipoprotein-associated phospholipase A2 (Lp-PLA2) has be
25                                              Lipoprotein-associated phospholipase A2 (Lp-PLA2) hydrol
26 e has been controversy regarding the role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in ath
27  sought to document the presence and role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in cal
28    The use of statins, PPARgamma agonists or lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibi
29                                              Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a n
30                                              Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a p
31                                              Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a r
32                                              Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an
33                                              Lipoprotein-associated phospholipase A2 (Lp-PLA2) is ass
34                       A 10% reduction in the lipoprotein-associated phospholipase A2 (Lp-PLA2) level
35                                              Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels
36 ata from over 50 000 patients that increased lipoprotein-associated phospholipase A2 (Lp-PLA2) mass o
37 olesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2 (Lp-PLA2) were m
38                                              Lipoprotein-associated phospholipase A2 (Lp-PLA2), a mem
39 ues regarding the precise role that secreted lipoprotein-associated phospholipase A2 (Lp-PLA2), also
40  (8, 12-iso-iPF(2 alpha)-VI isoform), plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), Merco
41 protein [hsCRP]), and vascular inflammation (lipoprotein-associated phospholipase A2 [Lp-PLA2]) were
42 leukin (IL) 6, soluble CD14 (sCD14), sCD163, lipoprotein-associated phospholipase A2 (LpPLA2), oxidiz
43 mmatory markers C-reactive protein (CRP) and lipoprotein-associated phospholipase A2 (LpPLA2).
44 ensity lipoprotein cholesterol, adiponectin, lipoprotein-associated phospholipase A2 mass and activit
45 tin, tumor necrosis factor-alpha receptor 2, lipoprotein-associated phospholipase A2 mass and activit
46 apolipoprotein B and A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 mass to risk sco
47 d reclassify 1.1%; lipoprotein(a), 4.1%; and lipoprotein-associated phospholipase A2 mass, 2.7% of pe
48 n(a); and 0.0018 (95% CI, 0.0010-0.0026) for lipoprotein-associated phospholipase A2 mass.
49 l clinical utility of lipoprotein-associated lipoprotein-associated phospholipase A2, myeloperoxidase
50 ere significantly associated with changes in lipoprotein-associated phospholipase A2 (n = 10; r = 0.6
51 tor-2 (P<0.001), interleukin-6 (P=0.04), and lipoprotein-associated phospholipase A2 (P=0.002), but n
52                                    Levels of lipoprotein-associated phospholipase A2 (platelet-activa
53 atelet-activating factor acetylhydrolase, or lipoprotein-associated phospholipase A2, plays a proathe
54 h-sensitivity C-reactive protein (hsCRP) and lipoprotein-associated phospholipase A2 were measured 1